Skip to main contentAI and Advanced
/
LINCOLN · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
LI
NSE · Equity shares · Biotechnology & Drugs-11.90 · -1.97%
Lincoln Pharmaceuticals LINCOLN
NSE:INR 590.7
BSE:INR 589
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for LINCOLN
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 602.6
Day rangeINR 586.1 — INR 609.95
52-week rangeINR 439.95 — INR 770
Volume33,074
Market cap1,157.01
P/E12.87
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)671.03
Net Income (INR Cr)87.89
Rev Growth (5 Year %)9.61
EPS Growth (5 Year %)7.12
P/E Ratio12.87
Book Value377.79
EPS43.88
Price/BV1.56Computed
Research path: Interpret Lincoln Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LINCOLNLincoln Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 890.4 | 797.01 | 700.29 |
| Cash Equivalents | 11.13 | Not available | Not available |
| Other Liabilities Total | 8.19 | 6.12 | 3.72 |
| Long Term Debt | 0 | Not available | Not available |
| Common Stock Total | 20.03 | 20.03 | 20.03 |
| Other Current Assets Total | 18.65 | 0.79 | 0.75 |
| Total Assets | 890.4 | 797.01 | 700.29 |
| Cash | 21.53 | 21.99 | 13.53 |
| Total Equity | 757.63 | 671.67 | 592.84 |
| Long Term Investments | 1.32 | 0 | 0 |
| Retained Earnings(Accumulated Deficit) | 737.6 | 587.35 | 508.61 |
| Total Common Shares Outstanding | 2 | 2 | 2 |
| Tangible Book Valueper Share Common Eq | 377.79 | 335.12 | 295.82 |
| Total Liabilities | 132.77 | 125.34 | 107.45 |
| Total Debt | 4.42 | 0 | 1.07 |
| Short Term Investments | 209.29 | 174.38 | 138.92 |
| Cashand Short Term Investments | 241.95 | 196.37 | 152.45 |
| Total Receivables Net | 242.35 | 223.64 | 215.98 |
| Notes Payable/Short Term Debt | 4.42 | 0 | 1.07 |
| Deferred Income Tax | 13.53 | 13 | 11.46 |
| Accounts Receivable-Trade Net | 161.45 | 166.56 | 161.83 |
| Property/Plant/Equipment Total-Net | 195.26 | 186 | 182.48 |
| Total Current Liabilities | 111.04 | 106.22 | 92.28 |
| Total Inventory | 80.11 | 78.68 | 77.17 |
| Accounts Payable | 84.86 | 84.95 | 72.44 |
| Other Currentliabilities Total | 21.76 | 13.33 | 11.83 |
| Total Long Term Debt | 0 | 0 | 0 |
| Intangibles Net | 0.92 | 0.44 | 0.33 |
| Other Long Term Assets Total | 2.9 | 3.82 | 4.67 |
| Note Receivable-Long Term | 106.94 | 106.81 | 66.07 |
| Total Current Assets | 583.06 | 499.94 | 446.74 |
| Accumulated Depreciation Total | Not available | -68.83 | -56.26 |
| Accrued Expenses | Not available | 7.93 | 6.94 |
| Other Equity Total | Not available | -0.32 | -0.42 |
| Prepaid Expenses | Not available | 0.46 | 0.4 |
| Additional Paid-In Capital | Not available | 64.62 | 64.62 |
| Property/Plant/Equipment Total-Gross | Not available | 250.36 | 235.26 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.12
Price to Sale Ratio1.72
Growth
Debt 5Yr CAGR %53.45
Margins
Operating Margin 12m12.4
Operating Margin 5y Avg15.03
Net Profit Margin 12m13.1
Net Profit Margin 5y14.2
Yield
Dividend Yield %0.3
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk53.29
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.3 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,375 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,977.25 | 1.69 L | 72.73 | — |
| Cipla | INR 1,405.6 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.45 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 49.78%
- FII
- 4.60%
- Other
- 45.62%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Lincoln Pharmaceuticals Ltd is Rated Hold - MarketsMojoMarket news · 17 Jul 2026, 1:53 am
Lincoln Pharmaceuticals Ltd is Rated Hold MarketsMojo
Lincoln Pharmaceuticals Ltd Actuals & Estimates (BSE:LINCOLN) - TradingViewMarket news · 26 Jun 2026, 10:32 am
Lincoln Pharmaceuticals Ltd Actuals & Estimates (BSE:LINCOLN) TradingView
Enterprise value to EBITDA forward of Lincoln Pharmaceuticals Ltd – NSE:LINCOLN - TradingViewMarket news · 25 Jun 2026, 11:15 pm
Enterprise value to EBITDA forward of Lincoln Pharmaceuticals Ltd – NSE:LINCOLN TradingView
Price to book forward of Lincoln Pharmaceuticals Ltd – NSE:LINCOLN - TradingViewMarket news · 25 Jun 2026, 8:31 pm
Price to book forward of Lincoln Pharmaceuticals Ltd – NSE:LINCOLN TradingView
Broad-Based Technical Strength Lifts Lincoln Pharmaceuticals Ltd to 52-Week High of Rs 770 - MarketsMojoMarket news · 13 Jun 2026, 2:45 am
Broad-Based Technical Strength Lifts Lincoln Pharmaceuticals Ltd to 52-Week High of Rs 770 MarketsMojo
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - MarketsMojoMarket news · 11 Jun 2026, 8:56 am
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals MarketsMojo
Corporate actions
Events
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.8000 per share(18%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Lincoln Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading pharmaceutical products, as well as undertaking contract manufacturing from pharmaceuticals companies across India and the globe. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, SVP injectables, dry-powder suspensions, liquid injection, and pharma products. It offers products for anti-infective, respiratory system, gynecology, cardio and CNS (central nervous system), antibacterial, dermatological infection, anti-diabetic, and anti-malaria. The Company is also engaged in building a portfolio of lifestyle and chronic segments, primarily in women’s healthcare and dermatology. The Company caters to approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. The Company has two manufacturing facilities located in Mehsana and Khatraj, Gujarat.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- LINCOLN
- BSE Code
- 531633
Questions
Stock FAQ
What is the symbol and ISIN of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has the symbol LINCOLN and ISIN - INE405C01035.
What is the current price of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals is currently trading at INR 590.70.
What are the year high and year low of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a year high of INR 770.00 and a year low of INR 439.95.
What is the market capitalization of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a market capitalization of INR 1,157.01 crore.
What is the P/E ratio of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a P/E ratio of 12.87.
What is the dividend yield of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a dividend yield of 0.30%.
How is the financial performance of Lincoln Pharmaceuticals based on revenue, net income, and EPS?
Lincoln Pharmaceuticals has revenue of INR 671.03 crore, net income of INR 87.89 crore, and EPS of INR 43.89.
What is the book value of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a book value of INR 377.79.
What is the debt-to-equity ratio of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Lincoln Pharmaceuticals?
Lincoln Pharmaceuticals has a price-to-book ratio of 1.56 and a price-to-sales ratio of 1.72.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.